Johnson & Johnson (NYSE:JNJ) Price Target Raised to $280.00

Johnson & Johnson (NYSE:JNJ) had its price objective upped by HSBC from $265.00 to $280.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HSBC’s price target points to a potential upside of 16.26% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on the company. Royal Bank Of Canada upped their target price on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. TD Cowen raised their target price on shares of Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Leerink Partners lifted their target price on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. Finally, Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $236.57.

Johnson & Johnson Stock Down 1.0%

NYSE JNJ traded down $2.35 during trading on Tuesday, hitting $240.84. 1,430,292 shares of the company traded hands, compared to its average volume of 8,924,616. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The business has a fifty day simple moving average of $232.69 and a 200 day simple moving average of $207.13. The company has a market capitalization of $580.09 billion, a P/E ratio of 21.78, a PEG ratio of 2.38 and a beta of 0.34. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion for the quarter. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Auto Owners Insurance Co raised its holdings in shares of Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after buying an additional 69,108,368 shares in the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $6,924,523,000. Capital World Investors acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $2,005,942,000. Laurel Wealth Advisors LLC increased its position in Johnson & Johnson by 15,040.6% in the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after purchasing an additional 7,371,687 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after buying an additional 3,731,074 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst raises price target to $280, arguing JNJ’s pipeline, recurring revenues and margin resilience justify more upside — this bullish call supports investor confidence in the stock’s further appreciation. Why One Analyst Thinks Johnson & Johnson Reaches $280
• Positive Sentiment: JNJ submitted a Type II variation to the European Medicines Agency seeking approval for TECVAYLI (teclistamab) in relapsed/refractory multiple myeloma — EU approval would materially expand oncology revenue potential. Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI
• Positive Sentiment: Early‑stage data for Erda‑iDRS in non‑muscle‑invasive bladder cancer met key endpoints (strong responses, durable control, manageable safety) — clinical progress can de‑risk future oncology catalysts and licensing/launch optionality. JNJ’s Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
• Positive Sentiment: Johnson & Johnson launched a pulsed field ablation (PFA) technology in Peru for atrial fibrillation, marking continued device expansion into emerging markets — incremental procedural/device revenue and share gains in electrophysiology. Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch
• Neutral Sentiment: Market commentary asks whether JNJ’s strong multi‑year run (large YTD/1‑year gains) leaves valuation stretched — this raises the risk of short‑term consolidation even if fundamentals remain intact. Is It Time To Reassess Johnson & Johnson (JNJ) After Strong Multi Year Share Price Gains

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.